Stenocare

0.354

DKK

-1.94 %

Less than 1K followers

STENO

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-1.94%

-14.9%

-70.74%

-51.25%

-71.45%

-90%

-94.57%

-96.27%

-97.41%

Stenocare is a Danish supplier of medical cannabis. Stenocare is the first player to have started sale of medical cannabis-based oils in Denmark. The company is now looking towards further European markets for its products. Stenocare is based in Randers, Denmark.

Market cap

13.59M DKK

Turnover

52.86K DKK

Revenue

4.76M

EBIT %

-695.17 %

P/E

-

Dividend yield-%

-

Financial calendar

8/5

2025

Interim report Q1'25

21/8

2025

Interim report Q2'25

6/11

2025

Interim report Q3'25

All

Press releases

3rd party

ShowingAll content types

Press release8 hours ago

Analyst Group: Analyst Group Comment on STENOCARE ASTRUM 10-10 Oil Being Approved for Reimbursement in Germany

Press releaseyesterday

STENOCARE ASTRUM 10-10 Oil Product Approved for Reimbursement in Germany

Press release3/31/2025, 6:00 AM

STENOCARE Begins Sales of New CBD100 Oil Product in Denmark

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release3/28/2025, 12:25 PM

STENOCARE interview with Proinvestor.com - Annual Report 2024

Regulatory press release3/27/2025, 7:01 AM

STENOCARE A/S publishes Annual Report 2024

Press release3/6/2025, 1:16 PM

Analyst Group: Equity Research Report on STENOCARE - All Focus on Astrum

Press release2/27/2025, 2:52 PM

Analyst Group: Analyst Group's Comment on STENOCARE’s Q4-report Report 2024

Regulatory press release2/27/2025, 8:04 AM

STENOCARE: Q4 and Annual Financial Statement Release 2024

Press release2/14/2025, 7:56 AM

STENOCARE - The innovative ASTRUM 10-10 product is now available for Australian patients

Press release1/29/2025, 9:52 AM

STENOCARE A/S Embarks on Strategic Transformation with HQ Relocation and Cultivation Facility Exit

Press release1/22/2025, 3:27 PM

Analyst Group: Analyst Group Comment on the Outcome of STENOCARE’s Conditional Rights Issue

Regulatory press release1/22/2025, 11:37 AM

STENOCARE A/S: Conditional Rights Issue subscribed to 45.0 percent

Press release1/20/2025, 11:29 AM

STENOCARE - Final deadline for Subscription to New Shares at DKK 0.50 Each

Press release1/17/2025, 7:00 AM

STENOCARE - Final deadline Soon for Subscription to New Shares at DKK 0.50 Each

Press release1/15/2025, 10:57 AM

STENOCARE - The new innovative ASTRUM 10-10 product is now available for German patients

Press release1/15/2025, 7:00 AM

STENOCARE - Deadline Soon for Subscription to New Shares at DKK 0.50 Each

Press release1/10/2025, 4:03 PM

STENOCARE A/S announces guarantee commitments in ongoing rights issue

Press release1/9/2025, 6:55 PM

STENOCARE - Deadline soon to subscribe for new shares at DKK 0.50 each

Press release1/7/2025, 10:22 AM

STENOCARE A/S: The subscription period in Stenocare's conditional rights issue begins today for the time limited offer of DKK 0,50 per new share

Press release1/3/2025, 10:21 AM

STENOCARE's Innovative ASTRUM 10-10 Product Now Available for Norwegian Patients

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.